CNS PharmaceuticalsCNSP
13F holders, Q2 2026 (June 30)11holders
4new positions
4sold out
$4.78avg. 13F price*
At the end of Q2 2026, 11 institutions reported holding CNS Pharmaceuticals Inc. (CNSP) in their 13F filings, unchanged from Q1 2026. 4 opened new positions and 4 sold out. The largest holders were Ikarian Capital, LLC ($649K), ADAR1 Capital Management, LLC ($335K) and Stonepine Capital Management, LLC ($199K).
- Company
- CNS Pharmaceuticals Inc.
- CUSIP
- 18978H508
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $417K |
| Exits | 4 | $56K |
All 13F filers, Q1 2026 → Q2 2026: 177,970 shares bought and 43,132 shares sold, net +134,838 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Ikarian Capital, LLC | 0.11% | Add +196.4% | 135,830 | $649K |
| ADAR1 Capital Management, LLC | 0.02% | New | 70,000 | $335K |
| Stonepine Capital Management, LLC | 0.15% | Reduce -31.9% | 41,573 | $199K |
| Boothbay Fund Management, LLC | 0.00% | No change | 13,524 | $65K |
| Vanguard Fiduciary Trust Co. | 0.00% | New | 10,226 | $49K |
| Vanguard Capital Management LLC | 0.00% | New | 6,993 | $33K |
| UBS Group AG | 0.00% | Add +100.4% | 1,461 | $7K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -39.0% | 799 | $4K |
| Barclays PLC | 0.00% | New | 19 | $91 |
| Barrett & Company, Inc. | 0.00% | No change | 8 | $38 |
| Danske Bank A/S | 0.00% | No change | 1 | $5 |
"% of holder's portfolio" is CNSP's weight in each manager's 13F, not the share of CNS Pharmaceuticals Inc. the manager owns.